$1.220
-0.020 (-1.61%)At close
PMVP News
PMVP Events
PMV Pharma Targets NDA Submission for rezatapopt in 2027
"The first quarter was one of continued execution as we advance the PYNNACLE study and remain on track to target an NDA submission for rezatapopt for platinum-resistant/refractory ovarian cancer in the first quarter of 2027," said David Mack, President and Chief Executive Officer of PMV Pharma. "We are also encouraged by the publication of the PYNNACLE Phase 1 results in the New England Journal of Medicine, which underscores the scientific innovation behind rezatapopt and highlights its potential to address a significant unmet medical need. Patients with TP53 Y220C advanced solid tumors, including platinum resistant ovarian cancer, experience poor outcomes despite available therapies."
PMV Pharmaceuticals Board Transition, Laurie Stelzer Appointed New Chair
PMV Pharmaceuticals (PMVP) announced a transition on its board of directors. Laurie Stelzer, who has served as a member of the board since 2020, has been appointed chair of the board, succeeding Rich Heyman, effective at the company's 2026 annual meeting of stockholders on June 4. Heyman's term as a member and chair of the board will expire at the meeting, and Heyman will not stand for reelection. Stelzer is a seasoned CFO and public company board director, most recently serving as CFO at Kailera Therapeutics (KLRA).
PMV Pharma Reports Positive Phase 2 Data for Rezatapopt
"2025 was an important and productive year for PMV Pharma as we reported positive Phase 2 interim data from the registrational PYNNACLE clinical trial and made significant progress in enrolling the study," said David Mack, CEO. "We look forward to submitting an NDA in the first quarter of 2027 for rezatapopt in platinum-resistant/refractory ovarian cancer."
PMV Pharma Cash Decreases to $112.9 Million
As of December 31, 2025, PMV Pharma had $112.9 million in cash, cash equivalents, and marketable securities, compared to $183.3 million at December 31, 2024. Net cash used in operations was $73.6 million for the year ended December 31, 2025, compared to $51.3 million for the year ended December 31, 2024.
PMV Pharmaceuticals Publishes Clinical Results of Rezatapopt for TP53 Mutant Tumors
PMV Pharmaceuticals announced that results from the Phase 1, first-in-human portion of the ongoing Phase 1/2 PYNNACLE study evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation were published in the New England Journal of Medicine, NEJM. The publication provides a summary of the Phase 1 safety and efficacy results across 77 patients. The study published in NEJM entitled, "Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors," highlighted the antitumor activity of rezatapopt in heavily pretreated patients across multiple solid tumor-types establishing proof-of-concept for p53 reactivation. In the Phase 1 portion of the PYNNACLE clinical trial, 77 heavily pretreated patients with advanced solid tumors harboring a TP53 Y220C mutation received oral rezatapopt across dose-escalation cohorts to determine the maximum tolerated dose and recommended Phase 2 dose, characterize safety, pharmacokinetics, and biomarker effects. Rezatapopt was generally well tolerated; dose-limiting toxicities were infrequent, supporting selection of the RP2D. Objective responses were observed across multiple tumor types. Clinical activity and biomarker data were consistent with selective binding to the Y220C pocket and restoration of wild-type p53 tumor suppressor function.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。